# Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

> **NCT01458886** · PHASE2 · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Asthma

## Interventions

- **DRUG:** BI 54903 MD
- **DRUG:** Placebo matching Respimat
- **DRUG:** Placebo matching Respimat
- **DRUG:** BI 54903

## Key facts

- **NCT ID:** NCT01458886
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-11
- **Primary completion:** 2013-05
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458886, "Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01458886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*